FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377989001> ?p ?o ?g. }

• W4377989001 abstract "Abstract Funding Acknowledgements Type of funding sources: None. Relevance of the problem. Anthracycline cardiotoxicity is the most unfavorable form due to irreversible complications of cardiovascular system caused by anthracyclines during the chemotherapy (CT) of the breast cancer (BC). Despite the fact that this type of cardiotoxicity has been studied better than others, the problem of preventing such complications remains relevant to this day. In our study, we suggest Trimetadizine (TMZ) as a cardioprotective agent in patients with disseminated breast cancer receiving Doxorubicin chemotherapy. Material and methods The study included 93 patients (aged 41.2±8.3 years) who underwent surgery for breast cancer and several courses of chemotherapy with Doxorubicin (according to the stage of breast cancer). Patients were randomized into 2 groups: the first group (n=47; G1) received TMZ at a dose of 70 mg daily, in the control group (n=46; G2) patients didn't receive TMZ. All patients before the start of the study underwent a complete echocardiographic examination and checked cardiac biomarkers such as troponin and brain natriuretic peptide (BNP). The exclusion criterion was patients with any kind of cardiovascular pathology. The primary endpoint of the study was a reduction in left ventricular ejection fraction (LVEF) deterioration as assessed by series of echocardiographic studies conducted after each course of chemotherapy, and then every 3 months after completion of chemotherapy for 1 year. Secondary outcome measures included echocardiographic (EchoCG) measurements of LV diastolic dysfunction, structural myocardial changes assessed by echocardiography, and control cardiac biomarkers. Results Both groups achieved the same cumulative dose of Doxorubicin. No patient died or discontinued chemotherapy during the study. There were no significant differences between the two groups in terms of baseline clinical findings, echocardiographic parameters, and changes in biomarkers. 3-5 months after the start of CT, standard echocardiography showed unreliable changes in LVEF, shortening fraction, and LV measurements. However, tissue Doppler showed a decrease in myocardial velocity (P = 0.001) in G2, indicating LV diastolic dysfunction. While no such changes were observed in G1. Conclusion Tissue Doppler proved to be more sensitive than standard echocardiography for early diagnosis of cardiac dysfunction, and TMZ appears to have a cardioprotective effect in case of anthracycline cardiotoxicity." @default.
• W4377989001 created "2023-05-25" @default.
• W4377989001 creator A5055041792 @default.
• W4377989001 date "2023-05-24" @default.
• W4377989001 modified "2023-10-01" @default.
• W4377989001 title "Cardio-protective effect of trimetazidine in patients with disseminated breast cancer" @default.
• W4377989001 doi "https://doi.org/10.1093/eurjpc/zwad125.019" @default.
• W4377989001 hasPublicationYear "2023" @default.
• W4377989001 type Work @default.
• W4377989001 citedByCount "0" @default.
• W4377989001 crossrefType "journal-article" @default.
• W4377989001 hasAuthorship W4377989001A5055041792 @default.
• W4377989001 hasBestOaLocation W43779890011 @default.
• W4377989001 hasConcept C121608353 @default.
• W4377989001 hasConcept C126322002 @default.
• W4377989001 hasConcept C143998085 @default.
• W4377989001 hasConcept C164705383 @default.
• W4377989001 hasConcept C168563851 @default.
• W4377989001 hasConcept C203092338 @default.
• W4377989001 hasConcept C2776694085 @default.
• W4377989001 hasConcept C2776802502 @default.
• W4377989001 hasConcept C2777927741 @default.
• W4377989001 hasConcept C2778198053 @default.
• W4377989001 hasConcept C2778233292 @default.
• W4377989001 hasConcept C2781303535 @default.
• W4377989001 hasConcept C36036425 @default.
• W4377989001 hasConcept C500558357 @default.
• W4377989001 hasConcept C530470458 @default.
• W4377989001 hasConcept C71924100 @default.
• W4377989001 hasConcept C78085059 @default.
• W4377989001 hasConceptScore W4377989001C121608353 @default.
• W4377989001 hasConceptScore W4377989001C126322002 @default.
• W4377989001 hasConceptScore W4377989001C143998085 @default.
• W4377989001 hasConceptScore W4377989001C164705383 @default.
• W4377989001 hasConceptScore W4377989001C168563851 @default.
• W4377989001 hasConceptScore W4377989001C203092338 @default.
• W4377989001 hasConceptScore W4377989001C2776694085 @default.
• W4377989001 hasConceptScore W4377989001C2776802502 @default.
• W4377989001 hasConceptScore W4377989001C2777927741 @default.
• W4377989001 hasConceptScore W4377989001C2778198053 @default.
• W4377989001 hasConceptScore W4377989001C2778233292 @default.
• W4377989001 hasConceptScore W4377989001C2781303535 @default.
• W4377989001 hasConceptScore W4377989001C36036425 @default.
• W4377989001 hasConceptScore W4377989001C500558357 @default.
• W4377989001 hasConceptScore W4377989001C530470458 @default.
• W4377989001 hasConceptScore W4377989001C71924100 @default.
• W4377989001 hasConceptScore W4377989001C78085059 @default.
• W4377989001 hasIssue "Supplement_1" @default.
• W4377989001 hasLocation W43779890011 @default.
• W4377989001 hasOpenAccess W4377989001 @default.
• W4377989001 hasPrimaryLocation W43779890011 @default.
• W4377989001 hasRelatedWork W1002865637 @default.
• W4377989001 hasRelatedWork W2042322799 @default.
• W4377989001 hasRelatedWork W2492256420 @default.
• W4377989001 hasRelatedWork W2591616149 @default.
• W4377989001 hasRelatedWork W2906367351 @default.
• W4377989001 hasRelatedWork W2909980364 @default.
• W4377989001 hasRelatedWork W2951069218 @default.
• W4377989001 hasRelatedWork W4298144793 @default.
• W4377989001 hasRelatedWork W4311789423 @default.
• W4377989001 hasRelatedWork W4367189272 @default.
• W4377989001 hasVolume "30" @default.
• W4377989001 isParatext "false" @default.
• W4377989001 isRetracted "false" @default.
• W4377989001 workType "article" @default.